Brii Biosciences
Latest round
- Series C
Last raised
- Mar 2021
Total raised
- $24M
Investors
- 3
About Brii Biosciences
Brii Biosciences Limited specializes in infectious disease treatments, with a headquarters in Beijing, China.48 billion in an IPO in July 2021.48 billion.Brii Biosciences specializes in developing innovative treatment options for infectious diseases, primarily addressing unmet medical needs associated with chronic conditions such as Hepatitis B and HIV. Their core product offerings include BRII-179, a treatment aimed at achieving higher HBsAg loss in patients with chronic Hepatitis B, and various novel therapeutic candidates designed for HIV. The products are engineered to provide first-in-class or different-in-class solutions, thereby enhancing treatment efficacy and patient outcomes where traditional options are limited. These treatment options target patient populations that often face social stigmas and inadequate access to care, significantly focusing on regions such as China and other international markets where the burden of infectious diseases is pronounced.Brii Biosciences generates revenue primarily through partnerships with healthcare providers and pharmaceutical distributors that facilitate the commercialization of its therapeutic products. The company engages in B2B transactions, collaborating with clinical research organizations and healthcare systems to promote its offerings, including flagship products like BRII-179. Revenue is structured around product sales and contractual agreements that may include milestone payments linked to clinical trial progress or regulatory approvals. Their clinical data presentations and updates reflect ongoing efforts to secure market access and expand the utilization of their treatments in key markets.48 billion from the IPO to advance its infectious disease project pipeline and expand its portfolio in central nervous system diseases. The company aims to introduce new therapeutic candidates targeting unmet medical needs within the next few years, with a particular focus on markets in Asia and beyond.
Who invested in Brii Biosciences
3 investors across 1 round
See all investors in Brii Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
Mar 23, 2021
Amount
$24M
Investors
Questions about Brii Biosciences
Who invested in Brii Biosciences?
Brii Biosciences has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Brii Biosciences raised?
Brii Biosciences has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Brii Biosciences last raise money?
Brii Biosciences's most recent round on record is a Series C, in Mar 2021.
What does Brii Biosciences do?
Brii Biosciences Limited specializes in infectious disease treatments, with a headquarters in Beijing, China.
Where is Brii Biosciences headquartered?
Brii Biosciences is headquartered in Beijing, China.
Which VCs invest in companies like Brii Biosciences?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Brii Biosciences's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Brii Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.